Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Guobin Li
Institution:
United Imaging Healthcare (China)
Observed institutions:
Second Affiliated Hospital of Zhengzhou University,
Affiliated Hospital of Qingdao University,
Second Affiliated Hospital of Soochow University,
United Imaging Healthcare (China)
ORCID:
0009-0009-5128-5783
Observed ORCID:
0009-0009-5128-5783
OpenAlex ID:
A5036502671
A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2024
·
Ying Kong
, Xinyue Zhao
, et al.
·
Molecular Cancer Therapeutics
·
12
Minimally invasive treatment of an ectopic kidney stone: a case report and literature review
2019
·
Chenglu Wang
, Lu Jin
, et al.
·
Journal of International Medical Research
·
8
Evaluation of Supracardiac Atherosclerosis in Stroke with a Noncontrast Head-Neck-Aortic Vessel Wall MRI
2026
·
Qianmei Jiang
, Zhe Zhang
, et al.
·
Radiology
·
1
Feasibility and safety of prostatic vaporization using 180W greenlight system in day surgery mode
2018
·
Ming Xu
, Kai Fu
, et al.
·
Zhonghua miniao waike zazhi
·
1
Figure S5 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026
·
Ying Kong
, Xinyue Zhao
, et al.
Figure S3 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026
·
Ying Kong
, Xinyue Zhao
, et al.
Figure S2 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026
·
Ying Kong
, Xinyue Zhao
, et al.
Figure S7 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026
·
Ying Kong
, Xinyue Zhao
, et al.
Table S4 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026
·
Ying Kong
, Xinyue Zhao
, et al.
Figure S1 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026
·
Ying Kong
, Xinyue Zhao
, et al.
Figure S4 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026
·
Ying Kong
, Xinyue Zhao
, et al.
Table S3 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026
·
Ying Kong
, Xinyue Zhao
, et al.
Table S2 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026
·
Ying Kong
, Xinyue Zhao
, et al.
Figure S6 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026
·
Ying Kong
, Xinyue Zhao
, et al.
Table S1 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026
·
Ying Kong
, Xinyue Zhao
, et al.
Table S5 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026
·
Ying Kong
, Xinyue Zhao
, et al.
Supplementary Figure legend from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2024
·
Ying Kong
, Xinyue Zhao
, et al.
Table S2 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2024
·
Ying Kong
, Xinyue Zhao
, et al.
Data from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2024
·
Ying Kong
, Xinyue Zhao
, et al.
Figure S3 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2024
·
Ying Kong
, Xinyue Zhao
, et al.
Figure S2 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2024
·
Ying Kong
, Xinyue Zhao
, et al.
Data from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2024
·
Ying Kong
, Xinyue Zhao
, et al.
Supplementary Methods from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2024
·
Ying Kong
, Xinyue Zhao
, et al.
Figure S7 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2024
·
Ying Kong
, Xinyue Zhao
, et al.
Table S4 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2024
·
Ying Kong
, Xinyue Zhao
, et al.
Show more works
View as search
Works count:
45
Citation count:
22
H-index:
2
I10-index:
1
Year
Topic
Type